Trade-Ideas LLC identified

Intra-Cellular Therapies

(

ITCI

) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Intra-Cellular Therapies as such a stock due to the following factors:

  • ITCI has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $19.8 million.
  • ITCI has traded 613,888 shares today.
  • ITCI is up 6.9% today.
  • ITCI was down 8.2% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ITCI with the Ticky from Trade-Ideas. See the FREE profile for ITCI NOW at Trade-Ideas

More details on ITCI:

Intra-Cellular Therapies, Inc., a biopharmaceutical company, discovers and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders within the central nervous system (CNS). Currently there are 6 analysts that rate Intra-Cellular Therapies a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Intra-Cellular Therapies has been 481,300 shares per day over the past 30 days. Intra-Cellular has a market cap of $1.3 billion and is part of the health care sector and drugs industry. Shares are down 48.5% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Intra-Cellular Therapies as a

hold

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity.

Highlights from the ratings report include:

  • ITCI has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 49.17, which clearly demonstrates the ability to cover short-term cash needs.
  • Compared to where it was trading a year ago, ITCI's share price has not changed very much due to (a) the relatively weak year-over-year performance of the overall market, (b) the company's stagnant earnings, and (c) other mixed results. Despite the fact that it has already risen in the past year, there is currently no conclusive evidence that warrants the purchase or sale of this stock.
  • ITCI, with its very weak revenue results, has greatly underperformed against the industry average of 1.9%. Since the same quarter one year prior, revenues plummeted by 100.0%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 401.3% when compared to the same quarter one year ago, falling from -$6.42 million to -$32.16 million.
  • The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Pharmaceuticals industry and the overall market, INTRA-CELLULAR THERAPIES INC's return on equity significantly trails that of both the industry average and the S&P 500.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.